Back to News
Market Impact: 0.2
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP says a class action lawsuit has been filed against Aardvark Therapeutics, alleging violations of Sections 10(b) and 20(a). The excerpt provides no further details on the allegations, potential damages, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
AARD-0.80
More News
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Trump created a committee to dig into the Fed's Lisa Cook. What is it and what comes next?
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Tesla’s ‘Full Self-Driving’ Becomes ‘Assisted Driving’ in Europe
- Humana Stock Jumps on Raised Medicare Advantage Ratings